Zolpidem tartrate, ACS – CAS 99294-93-6
€ 960.00
Additional information
| Weight | 1 g |
|---|---|
| product name | Zolpidem tartrate, ACS |
| features | pharmaceutical secondary standard |
| synonyms | Bis[N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide (2R,3R)-2,3-dihydroxybutanedioate |
| product origin | 100% made in European Union (according to USP, EUP, ECHA-REACH) |
| purity grade | >99.99% (raw virgin matter, ultra-pure, concentrated, sterilized) |
| use | lab. / tech. / bio-research / pharmaceutical |
| product code | ES8188A |
| C.A.S. number | 99294-93-6 |
| MDL | MFCD31561831 |
| EINECS | 200-659-6 |
| SMILES string | C(C(N(C)C)=O)C1=C(N=C2N1C=C(C)C=C2)C3=CC=C(C)C=C3.[C@@H]([C@H](C(O)=O)O)(C(O)=O)O |
| InChl key | =NYVVVBWEVRSKIU-LREBCSMRSA-N |
| empirical formula | C38H42N6O2·C4H6O6 |
| molecular formula | C19H21N3O.1/2C4H6O6 |
| formula weight | 764.87 g/mol |
| melting point | 196 °C |
| solubility | slightly soluble in water, sparingly soluble in methanol, practically insoluble in methylene chloride |
| stability | the product is chemically stable under standard ambient conditions (room temperature) |
| sensitivity & storage | ambient temperature (2 °C to 8 °C) |
| assay | >99.99% to <102.50% |
| appearance (color) | white to off-white |
| form | powder |
| description | Zolpidem tartrate (zolpidemtartrate) is a non-benzodiazepine sedative-hypnotic drug with chemical name N, N, 6-trimethyl-2-(4 -methylphenyl) Imidazo[1,2-a]pyridine-3-acetamide tartrate, Zolpidem tartrate has the advantages of fast treatment of insomnia, prolonged sleep time, no rebound after drug withdrawal, small side effects, and no respiratory depression; clinical studies have shown that zolpidem can selectively act on the BZ1 (ω1) subtype of the benzodiazepine binding site, increasing the affinity of GA-BA (γ-aminobutyric acid) to the GABA receptor, making chloride the opening of ion channels causes the cell membrane to become supercharged, thereby inhibiting the firing of neurons, resulting in central nervous system depression; the drug has no obvious rebound or withdrawal reaction after withdrawal, and has a relatively significant effect on primary insomnia and insomnia caused by stroke, depression, schizophrenia, etc. |
| note (1) | incompatible materials : |
| note (2) | <span style="font-weight:700; color:red;"> this product is for research use only, is not to be used for therapeutic ; not intended for animal or human or diagnostic or therapeutic use , and cannot be sold to patients.</span> |
| note (3) | described price of the product is NOT NEGOTIABLE , already around 25% lower than the official price of the International Chemical Stock Exchange / ICIS . <span style="color:red; font-weight:700; font-size:1.5em;">*</span> <span style="font-weight:700;">Possible additional discount for large quantity orders .</span> |
| packaging / transport | special for chemical transport (according to IATA / ADR / ECHA-REACH rules / int.l laws) . |
| certifications | C.O.A., MSDS, GMP, API, USP, EUP, ECHA-REACH, ORIGIN, etc… (originals will be delivered with good , and copies after confirmed order) |
Reviews
There are no reviews yet.